プロテオミクスアプローチによる新たな標的の発見 (InnovRT1) (InnovRT1)
ラブドイド腫瘍の不均一性 : 新しい治療標的を特定するためのプロテオミクスおよび単細胞解析
The investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a wide series of rhabdoid tumors, from both intra and extra cranial origins.
調査の概要
詳細な説明
Context: Rhaboid tumors (RT) are aggressive cancers of young infants, exposed to the toxicity of heavy treatments often ineffective, which justifies the need to identify new treatment strategies. These tumors are characterized by the biallelic alteration of SMARCB1 gene, encoding one of the subunits of the SWI/SNF complex, a chromatin remodeler. These mutations are the only ones found in these very stable cancers, which offers few therapeutic targets that can be identified by genomic techniques. They are morphologically undifferentiated and pluriphenotypic, suggesting the existence of a cellular diversity still poorly described. To advance on these questions, the investigators' laboratory has developed a model of genetically engineered mouse model spontaneously developing RT, biologically very similar to their human counterparts.
Objectives and methods: The investigators' project aims to describe the proteomic and phosphoproteomic signatures of these tumors, so far described at the genome and transcriptome level; an integration of these pangenomic / pan-proteomic studies will reveal the most relevant features to target. The investigators will fully characterize the proteomic and phosphoproteomic landscape using mass spectrometry on a cohort of clinically, radiologically and histopathologically annoted ATRT, for which methylome and RNAseq profiling will also be done. The investigators will describe the proteomic features of each molecularly defined subgroups, and aim to correlate RNAseq changes with proteomic features.
Patients will be included if they or their legal representative have given a consent to such a study, and if frozen material is stored at Necker Hospital.
Expected results: This analysis helps to identify how to articulate several innovative therapeutic approaches, taking into account both the diversity of the cells to be treated, and the real targets, proteins, to inhibit or restore.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Paris、フランス、75015
- Service de neurochirurgie - Hôpital Necker Enfants malades
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
cohort of clinically, radiologically and histopathologically annoted ATRT
説明
Inclusion Criteria:
- Aged 0-17 years old
- Rhabdoid tumor, treated in oncology departments in Ile de France
- frozen samples collected in usual care
- parents' agreement for samples collection in usual care
Exclusion Criteria
- Unconfirmed diagnosis of Rhabdoid tumor with molecular analyses Samples
- paraffin embedded tissues
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
ATRT
Patients <18 years with an ATRT having frozen samples |
Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
ATRTの各分子サブグループのプロテオミクスサインの同定
時間枠:3年
|
3年
|
協力者と研究者
捜査官
- スタディディレクター:Kevin Beccaria, MD, PhD、APHP Assistance Publique des Hôpitaux de Paris
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。